Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study
Bibliographic record
Abstract
Background/Purpose: Risankizumab (RZB) is an approved, optimized inhibitor of IL-23 for treating adults with moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease and ulcerative colitis. VALUE is a post-marketing observational study (PMOS) assessing the durability of response of RZB in real world practice. In this post hoc analysis, we report the interim drug survival of RZB and other biologic therapies (OtherBios) in a subgroup of patients with PsO and concomitant PsA. Methods: VALUE (NCT03982394) is a multi-country, prospective PMOS. This post hoc analysis includes data from the subset of patients with PsO who were also diagnosed with concomitant PsA by a rheumatologist. Drug survival, defined as patients staying on the biologic they initiated at study enrollment, was assessed using the proportion of patients with treatment substance changes, and the cumulative probability of treatment changes. Treatment results were compared as RZB vs OtherBios at 25 months and RZB vs TNFα inhibitor (TNFi) vs IL-17i at 25 months. Results are reported from an interim database lock on 09 December 2024. All enrolled patients who received at least one dose of study medication were included in this treatment substance change analysis. Propensity score matching (PSM) with a 1:1 ratio using greedy algorithm and exact match for biologic-naive/biologic-experienced status was used to account for group imbalances. Nominal P values are reported. Results: This interim analysis included 255 (RZB) and 207 (OtherBios) patients diagnosed with PsO and concomitant PsA. Patients treated with RZB were older (53.5 years vs 49.3 years, P < 0.05) and had more severe skin disease as assessed by baseline psoriasis area and severity index (RZB vs OtherBios), (15.0 vs 13.1, P < 0.05), and body surface area (24.0% vs 19.1%, P < 0.05) than patients treated with OtherBios. Differences were balanced in the PSM set and results from PSM set are shown below. Patients receiving RZB were significantly less likely to require a treatment substance change than those receiving OtherBios (12.6% vs 30.3%, P <0.05) at month 25 of treatment. The probability of treatment substance change (95% CI) at month 25 based on the Kaplan-Meier curve for time to first treatment substance change was 0.11 (0.06, 0.17) for patients receiving RZB vs 0.31 (0.23, 0.41) for patients receiving OtherBios (P < 0.05). In assessing drug survival by mechanism of action (RZB as reference vs TNFi vs IL-17i) at 25 months, patients receiving RZB were less likely to require a treatment substance change (12.6% vs. 43.8% vs 26.4%, P <0.05). The probability of treatment substance change (95% CI) at month 25 based on the Kaplan-Meier curve for time to first treatment change was 0.11 (0.06, 0.19) in the RZB group, 0.44 (0.28, 0.63) in the TNFi group, and 0.28 (0.18, 0.44) in the IL-17i group (P < 0.05). Conclusion: Patients with PsO and concomitant PsA who were treated with RZB in real-world practice had higher drug survival and were less likely to require treatment changes compared to patients receiving OtherBios including TNFi and IL-17i.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.010 | 0.010 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.005 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".